top of page

Biopharma Pulse - 5/16-5/20 Week in Review

  • Writer: BPIQ
    BPIQ
  • May 20, 2022
  • 2 min read

As we have reached the middle of May, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.

Table 1. BPIQ company weekly/monthly moves and YTD moves

Category

Weekly Move (5/9-5/13)

YTD Move

All BPIQ Companies

+2.18%

-45.87%

CAR-T Companies

+4.58%

-46.28%

Gene Editing Companies

+2.99%

-53.45%

XBI

+2.52%

-37.18%

See the biggest moves from last week below:

Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!

*We never send you spam - unsubscribe anytime



Highlights for the week of 5/16-5/20


Biggest positive move

  • $BMEA +69.4% Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3


Biggest negative move

  • $EVFM -64.0% Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering




Additional big moves

  • $RVVTF +66.7% Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

  • $SIGA +66.2% SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

  • $CRBP +61.9%

  • $IDRA +48.6% Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

  • $IMNM +47.3% Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

  • $CALT +38.9% Calliditas receives positive CHMP opinion in IgA nephropathy

  • $PCSA +35.9% Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

  • $ACRX +27.6% AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®

  • $CALT +18.0% Calliditas receives positive CHMP opinion in IgA nephropathy

  • $SIGA +17.1% SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat

  • $IDRA +16.0% Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

  • $GRTX +13.3% Galera Announces Plan to Submit Avasopasem NDA by Year End

  • $CRDL +11.0% Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis.

  • $INAB -11.4% IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform.

  • $TNXP -13.1% Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2

  • $CABA -13.3% Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

  • $KROS -16.6% Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers.

  • $ENTA -17.3% Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

  • $AMTI -18.5% Applied Molecular Transport Provides Strategy Update.

  • $APRE -19.1% Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

  • $VALN -20.6% Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

  • $FHTX -25.8% Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

  • $TNXP -39.7% Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split

  • $APRE -44.5% Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

  • $CMRX -44.6% Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

  • $ATHX -55.2% Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study.

  • $ENDP -60.8% Drugmaker Endo Begins Debt-Restructuring Talks With Creditors Amid Opioid Litigation







Highlights for next week

  • To see next week's Big Movers HERE, subscribe. Learn more here.

  • $VRCA VP-102 PDUFA target action date




See our Big Movers post to learn about upcoming Movers throughout May and PDUFAs, after subscribing. Learn more here.



 
 
 

Comments

bottom of page